Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML
Status:
Completed
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated
t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation